Tardive dyskinesia update: treatment and management
- 8 October 2018
- journal article
- research article
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 25 (2) , 78-89
Abstract
SUMMARY: The development of rational treatments for tardive dyskinesia has been held back by limitations to our understanding of its aetiology, which even now does not extend far beyond its association with centrally acting dopamine-blocking drugs. This article reviews briefly the major aetiological theories and addresses general management and specific treatment options. Primary prevention and early recognition remain the crucial management issues because, once the condition is established, there are no satisfactory treatments. The article considers two newly developed drugs, valbenazine and deutetrabenazine, in some detail as, although they are not yet licensed in Europe, they have largely been responsible for an upsurge in interest in tardive dyskinesia in the North American literature and are likely to be widely promoted in the future. Although possessed of undoubted benefits, the evidence suggests that these represent small steps rather than large leaps forward in treatment.LEARNING OBJECTIVES: •Be able to discuss the major aetiological theories on the causation of a common, and sometimes serious, adverse action of antidopaminergic drugs •Understand general management and specific treatment options •Understand the pharmacology and efficacy of two drugs recently approved by the FDA for the treatment of tardive dyskinesia DECLARATION OF INTEREST: D.C.O. is psychiatric commissioner on the Commission on Human Medicines, the UK drug regulator, and chair of its expert advisory group on CNS drugs. He is also a member of the psychiatry Scientific Advisory Group of the European Medicines Agency.Keywords
This publication has 60 references indexed in Scilit:
- Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesisMovement Disorders, 2012
- Extract ofGinkgo bilobaTreatment for Tardive Dyskinesia in SchizophreniaThe Journal of Clinical Psychiatry, 2010
- Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in ratsJournal of Neural Transmission, 2009
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Protective effect of rutin, a polyphenolic flavonoid against haloperidol‐induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changesFundamental & Clinical Pharmacology, 2007
- Treatment of Tardive Dyskinesia With GalantamineThe Journal of Clinical Psychiatry, 2007
- Dosing of Quetiapine in SchizophreniaThe Journal of Clinical Psychiatry, 2005
- Maintenance Treatment of Severe Tardive Dyskinesia With ClozapineJournal of Clinical Psychopharmacology, 2005
- The use of videotaped assessment in relation to a study of enhanced management in treatment-resistant schizophreniaJournal of Psychopharmacology, 1997
- Prevention/treatment of tardive dyskinesiaActa Psychiatrica Scandinavica, 1981